Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302

BACKGROUND: Hypoxic niches in solid tumors harbor therapy-resistant cells. Hypoxia-activated prodrugs (HAPs) have been designed to overcome this resistance and, to date, have begun to show clinical efficacy. However, clinical HAPs activity could be improved. In this study, we sought to identify non-...

Descripción completa

Detalles Bibliográficos
Autores principales: Wojtkowiak, Jonathan W, Cornnell, Heather C, Matsumoto, Shingo, Saito, Keita, Takakusagi, Yoichi, Dutta, Prasanta, Kim, Munju, Zhang, Xiaomeng, Leos, Rafael, Bailey, Kate M, Martinez, Gary, Lloyd, Mark C, Weber, Craig, Mitchell, James B, Lynch, Ronald M, Baker, Amanda F, Gatenby, Robert A, Rejniak, Katarzyna A, Hart, Charles, Krishna, Murali C, Gillies, Robert J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310189/
https://www.ncbi.nlm.nih.gov/pubmed/25635223
http://dx.doi.org/10.1186/s40170-014-0026-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310189/
https://www.ncbi.nlm.nih.gov/pubmed/25635223
http://dx.doi.org/10.1186/s40170-014-0026-z

Ejemplares similares